This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
SparkCures ID | 1296 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 74 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Phase 1
Phase 2
Key Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.
Learn more about how we work with trial sponsors